Medtech executives expect the technology to help fuel their companies’ future growth. Boston Scientific CEO Mike Mahoney has ...

Field Medical announced today that it received FDA breakthrough device designation for its FieldForce pulsed field ablation ...

Pulsed field ablation could soon be used in the majority of electrophysiology procedures to treat atrial fibrillation as ...

FARAPULSE™ from Boston Scientific procedure was performed on Tuesday, April 16. Saint Agnes says the hospital went on to treat two more patients using the new technology. During a traditional ...

The procedure is called “Farapulse,” first performed on a patient at ECU Health about three weeks ago. The Farapulse is a new device that can help treat A-FIB, a common disease that causes an ...

However, Boston Scientific shares were volatile last week, as investors weighed a Q3 earnings beat against a disappointing update on the FARAPULSE trial. BSX's recent price action has been ...

The company’s Farapulse PFA system, which gained Food and Drug Administration approval in January, is not indicated to treat persistent AFib. Spokesperson Chanel Hastings told MedTech Dive in an ...

BSX’s outperformance over the past year can be primarily attributed to its differentiated portfolio, strategic acquisitions like Farapulse, its category leadership strategy, and robust ...

Citi raised the firm’s price target on Boston Scientific (BSX) to $107 from $98 and keeps a Buy rating on the shares. The firm also added the ...

Four PFA systems have launched in the U.S. in the past year: Medtronic’s PulseSelect and Affera Sphere-9, Boston Scientific’s Farapulse and J&J's Varipulse. The Citi survey polled 36 ...